• Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
• Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
• Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
• Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
• Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
• Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
• Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.

Duration: July 14, 2021 to present

General Issues: Budget/Appropriations, Health Issues, Medicare/Medicaid, Civil Rights/Civil Liberties, Immigration, Medical/Disease Research/Clinical Labs, Tobacco, Taxation/Internal Revenue Code

Spending: about $889,725 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2021: U.S. Senate, House of Representatives, Office of Science & Technology Policy (OSTP), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Homeland Security - Dept of (DHS), President of the U.S.